***Welcome to Stillman Translations preliminary onboarding assessment!***

*This assessment has 5 sections. Make sure to follow the instructions and complete all the information needed.*

*The goal of this request is to analyze your performance and your potential.*

*Breathe in and out, and do your best. Hope we can count on you soon!*

**SECTION 1. INSTRUCTIONS**

Below you will find a special instruction for section 3:

\*Please make sure target text mirrors source format.

\*Normalize spaces.

**SECTION 2. GLOSSARY**

*In this section, you are required to complete this task:*

*\*Extract four terms (cells 1 to 4) from the text in Section 3 that you consider are worth being in the glossary.*

|  |  |  |
| --- | --- | --- |
|  | **Source** | **Target** |
| 1 | atopic dermatitis | dermatitis atópica |
| 2 | prescription medicine | medicamento con receta |
| 3 | chronic rhinosinusitis with nasal polyps (CRSwNP) | rinosinusitis crónica con pólipos nasales (RSCcPN) |
| 4 | healthcare provider | proveedor de atención médica |

**SECTION 3. TRANSLATION**

Please, add your sample translation below (between 300-500 words). Bear in mind this should be the best sample of your work!

|  |  |
| --- | --- |
| **Source** | **Target** |
| **What is DRUGXX?** | **¿Qué es DRUGXX?** |
| DRUGXX is a prescription medicine used to treat people aged 6 or older with moderate-to-severe atopic dermatitis (eczema) that cannot be controlled appropriately with prescribed therapies applied on skin (topical) or in cases in which topical therapies cannot be used. | DRUGXX es un medicamento con receta utilizado para tratar a personas de 6 años de edad o más con dermatitis atópica (eczema) moderada a grave que no puede controlarse correctamente con terapias recetadas que se aplican sobre la piel (tópicas) o en casos en los que no se puedan utilizar terapias tópicas. |
| DRUGXX may be used with or without topical corticosteroids. | DRUGXX puede utilizarse con o sin corticosteroides tópicos. |
| It is used with other asthma medicines for the maintenance therapy of moderate-to-severe asthma in people aged 12 years and older whose asthma is not controlled with their current asthma medicines. | Se usa con otros medicamentos para el asma para la terapia de mantenimiento del asma moderada a grave en personas de 12 años y más cuya asma no se encuentra bajo control con sus medicamentos para el asma actuales. |
| DRUGXX helps prevent severe asthma attacks (exacerbations) and can improve breathing. | DRUGXX ayuda a prevenir ataques graves de asma (reagudizaciones) y puede mejorar la respiración. |
| DRUGXX may also help reduce the amount of oral corticosteroids you need and, at the same time, prevent severe asthma attacks and improve breathing. | DRUGXX también puede ayudar a reducir la cantidad de corticosteroides orales que necesita y, a la vez, prevenir ataques graves de asma y mejorar la respiración. |
| It is used with other medicines for the maintenance therapy of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is uncontrolled. | Se usa con otros medicamentos para la terapia de mantenimiento de la rinosinusitis crónica con pólipos nasales (RSCcPN) en adultos cuya enfermedad no esté controlada. |
| DRUGXX is not used to treat sudden respiratory problems. | DRUGXX no se utiliza para tratar problemas respiratorios repentinos. |
| DRUGXX acts by blocking two proteins which contribute to a type of inflammation which plays an important part in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps. | DRUGXX actúa bloqueando dos proteínas que contribuyen a un tipo de inflamación que desempeña un papel importante en la dermatitis atópica, el asma y la rinosinusitis crónica con pólipos nasales. |
| * It is not known whether DRUGXX is safe and effective in children younger than 6 years of age who have atopic dermatitis. * It is not known whether DRUGXX is safe and effective in children younger than 12 years of age who have asthma. * It is not known whether DRUGXX is safe and effective in children under 18 years of age with chronic rhinosinusitis with nasal polyps. | * Se desconoce si DRUGXX es seguro y eficaz en personas menores de 6 años con dermatitis atópica. * Se desconoce si DRUGXX es seguro y eficaz en personas menores de 12 años con asma. * Se desconoce si DRUGXX es seguro y eficaz en personas menores de 18 años con rinosinusitis crónica con pólipos nasales. |
| Before using DRUGXX, tell your healthcare provider about all of your medical conditions, including the following:   * If you have eye problems. * If you have a parasitic (helminths) infection. * If you are scheduled to receive any type of vaccinations. You should not receive any live vaccines if you are receiving DRUGXX. * If you are pregnant or are planning to become pregnant. It is not known whether DRUGXX can harm the fetus. | Antes de usar DRUGXX, infórmele a su proveedor de atención médica sobre todas sus afecciones médicas, incluido lo siguiente:   * Si tiene problemas oculares. * Si tiene una infección parasitaria (helmintos). * Si tiene programado recibir algún tipo de vacuna. No debe recibir ninguna vacuna elaborada con microbios vivos si recibe tratamiento con DRUGXX. * Si está embarazada o planea quedar embarazada. Se desconoce si DRUGXX puede dañar al feto. |
| **How should I use DRUGXX?** | **¿Cómo debo utilizar DRUGXX?** |
| Use DRUGXX exactly as prescribed by your healthcare provider.  Your healthcare provider will tell you how much DRUGXX to inject and how often you should do it. | Utilice DRUGXX exactamente como se lo recetó su proveedor de atención médica.  Su proveedor de atención médica le dirá cuánto DRUGXX debe inyectar y con qué frecuencia debe hacerlo. |
| DRUGXX is available in a single-dose prefilled syringe with needle guard or in a prefilled pen. | DRUGXX viene en una jeringa precargada de dosis única con protector de aguja o en una pluma precargada. |
| DRUGXX is given as an injection under the skin (subcutaneous injection). | DRUGXX se administra en forma de inyección debajo de la piel (inyección subcutánea). |
| If your healthcare provider decides that you or a caregiver can administer DRUGXX injections, you or your caregiver should receive training on how to properly prepare and inject DRUGXX. | Si su proveedor de atención médica decide que usted o un cuidador pueden administrar las inyecciones de DRUGXX, usted o su cuidador deben recibir capacitación sobre la manera correcta de preparar e inyectar DRUGXX. |
| Do not try to inject DRUGXX until your healthcare provider has shown you the right way to do it. | No intente inyectar DRUGXX hasta que su proveedor de atención médica le haya mostrado la manera correcta de hacerlo. |

**SECTION 4. QUESTIONS AND COMMENTS**

We also need to check your capacity to spot potential issues beforehand.

In the table below, please list your questions and comments in relation with this test:

1. Challenging sections from the source text or sections you are unsure of should be copied or inserted into the **Source Text** column.

2. Write your translation in the **Target Text** column.

3. Doubts and comments should be written in English.

|  |  |  |
| --- | --- | --- |
| Source Text | Target Text | Question / Comment  (in English) |
| rhinosinusitis with nasal polyps (CRSwNP) | rinosinusitis crónica con pólipos nasales (RSCcPN) | I decided to translate the acronym since it is widely used in Spanish. Please, let me know if that’s ok with you. Other options could be:   * Spanish translation (English translation, English ACRONYM) * Spanish translation (English ACRONYM, por sus siglas en inglés) |
| children younger than (6, 12, 18 years old) | personas menores de (6, 12, 18 años) | I used “personas” (people) instead of “children” (niños) since for the ages between 13 and 18 we would be talking about teenagers, not children per se. Also, in this way we can unify the term to be precise for all ages. |
| DRUGXX | DRUGXX | This was left in English, as it is the name of the drug (it was changed to keep client confidentiality). |
|  |  |  |
|  |  |  |

**SECTION 5. REFERENCES**

In the table below, please list the reference material you have consulted to carry out this test.

1. Please introduce the **Reference source** (including publisher and full title as appropriate) in the first column.
2. Specify if your reference source is general or specific. If specific, clarify which term or section the reference covers.

|  |  |
| --- | --- |
| Reference Source | General / Specific (Term) |
| National Eczema Association. Atopic Dermatitis: <https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/> | General information about atopic dermatitis. |
| Diccionario crítico de dudas de medicina, inglés-español. Navarro (el Libro Rojo). | Specific term: “severe”.  Specific term: “exacerbation”. |
| Medlineplus. Subcutaneous (SQ) injections (bilingual source): <https://medlineplus.gov/ency/patientinstructions/000430.htm#:~:text=Subcutaneous%20(SQ%20or%20Sub%2DQ,Blood%2Dthinners> | Specific term: “subcutaneous injection”. |
| Science Direct. Utilidad de la mucoplastia endonasal en el tratamiento quirúrgico de la rinosinusitis crónica con pólipos nasales. Estudio prospectivo: <https://www.sciencedirect.com/science/article/abs/pii/S0001651920301655> | Specific term: “chronic rhinosinusitis with nasal polyps”. |
| Cosnautas: <http://www.cosnautas.com/es/libro/31954-live-vaccine> | Specific term: “live vaccine”. |

Thanks!